Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study

ConclusionsNon-inferior efficacy of CMAB008 to innovator infliximab is illustrated with similar early and lasting therapeutic effects, and the equivalence is further demonstrated. CMAB008 is well tolerated and has semblable safety compared with the innovator infliximab.Trial registration numberNCT03478111.

http://link.springer.com/10.1007/s40744-023-00544-2

Source: Rheumatology and Therapy - March 25, 2023 Category: Rheumatology Source Type: research